良性前立腺肥大症の世界市場（～2026年）

• 英文タイトル：Global Benign Prostatic Hyperplasia Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY11036
• 出版社/出版日：QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、90ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は良性前立腺肥大症のグローバル市場について調査・分析したレポートです。種類別（薬物療法、透析、その他）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別良性前立腺肥大症の競争状況、市場シェア
・世界の良性前立腺肥大症市場：種類別市場規模 2015年-2020年（薬物療法、透析、その他）
・世界の良性前立腺肥大症市場：種類別市場規模予測 2021年-2026年（薬物療法、透析、その他）
・世界の良性前立腺肥大症市場：用途別市場規模 2015年-2020年（病院、クリニック）
・世界の良性前立腺肥大症市場：用途別市場規模予測 2021年-2026年（病院、クリニック）
・北米の良性前立腺肥大症市場分析：米国、カナダ
・ヨーロッパの良性前立腺肥大症市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの良性前立腺肥大症市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の良性前立腺肥大症市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの良性前立腺肥大症市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Abbott、Allergan、Astellas Pharma、Boehringer Ingelheim Pharma、Eli Lilly and Company、GlaxoSmithKline、Merck、Pfizer、Sanofi
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Benign prostatic hyperplasia (BPH) also known as benign prostatic hypertrophy is characterized by the unusual propagation of the prostatic cells, which causes difficulties like urinary retention and infections of the urinary tract. It is most common among the aging men population, primarily driving this market. On the basis of geographical analysis, the North American region is expected to retain its dominance in this market owing to better healthcare infrastructure, high healthcare expenditure on urological disorders, increased awareness in the society increasing the outpatients center and hospitals visits.

Market Analysis and Insights: Global Benign Prostatic Hyperplasia Market
The global Benign Prostatic Hyperplasia market size is projected to reach US$ 10540 million by 2026, from US$ 10020 million in 2020, at a CAGR of 4.8%% during 2021-2026.

Global Benign Prostatic Hyperplasia Scope and Market Size
Benign Prostatic Hyperplasia market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Benign Prostatic Hyperplasia market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Abbott
Allergan
Astellas Pharma
Boehringer Ingelheim Pharma
Eli Lilly and Company
GlaxoSmithKline
Merck
Pfizer
Sanofi

Market segment by Type, the product can be split into
Drug Therapy
Dialysis
Other
Market segment by Application, split into
Hospitals
Clinics

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Revenue
1.4 Market by Type
1.4.1 Global Benign Prostatic Hyperplasia Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Drug Therapy
1.4.3 Dialysis
1.4.4 Other
1.5 Market by Application
1.5.1 Global Benign Prostatic Hyperplasia Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia Market Perspective (2015-2026)
2.2 Global Benign Prostatic Hyperplasia Growth Trends by Regions
2.2.1 Benign Prostatic Hyperplasia Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Benign Prostatic Hyperplasia Historic Market Share by Regions (2015-2020)
2.2.3 Benign Prostatic Hyperplasia Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Benign Prostatic Hyperplasia Market Growth Strategy
2.3.6 Primary Interviews with Key Benign Prostatic Hyperplasia Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Benign Prostatic Hyperplasia Players by Market Size
3.1.1 Global Top Benign Prostatic Hyperplasia Players by Revenue (2015-2020)
3.1.2 Global Benign Prostatic Hyperplasia Revenue Market Share by Players (2015-2020)
3.1.3 Global Benign Prostatic Hyperplasia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Benign Prostatic Hyperplasia Market Concentration Ratio
3.2.1 Global Benign Prostatic Hyperplasia Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Revenue in 2019
3.3 Benign Prostatic Hyperplasia Key Players Head office and Area Served
3.4 Key Players Benign Prostatic Hyperplasia Product Solution and Service
3.5 Date of Enter into Benign Prostatic Hyperplasia Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Benign Prostatic Hyperplasia Historic Market Size by Type (2015-2020)
4.2 Global Benign Prostatic Hyperplasia Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Benign Prostatic Hyperplasia Market Size by Application (2015-2020)
5.2 Global Benign Prostatic Hyperplasia Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Benign Prostatic Hyperplasia Market Size (2015-2020)
6.2 Benign Prostatic Hyperplasia Key Players in North America (2019-2020)
6.3 North America Benign Prostatic Hyperplasia Market Size by Type (2015-2020)
6.4 North America Benign Prostatic Hyperplasia Market Size by Application (2015-2020)

7 Europe
7.1 Europe Benign Prostatic Hyperplasia Market Size (2015-2020)
7.2 Benign Prostatic Hyperplasia Key Players in Europe (2019-2020)
7.3 Europe Benign Prostatic Hyperplasia Market Size by Type (2015-2020)
7.4 Europe Benign Prostatic Hyperplasia Market Size by Application (2015-2020)

8 China
8.1 China Benign Prostatic Hyperplasia Market Size (2015-2020)
8.2 Benign Prostatic Hyperplasia Key Players in China (2019-2020)
8.3 China Benign Prostatic Hyperplasia Market Size by Type (2015-2020)
8.4 China Benign Prostatic Hyperplasia Market Size by Application (2015-2020)

9 Japan
9.1 Japan Benign Prostatic Hyperplasia Market Size (2015-2020)
9.2 Benign Prostatic Hyperplasia Key Players in Japan (2019-2020)
9.3 Japan Benign Prostatic Hyperplasia Market Size by Type (2015-2020)
9.4 Japan Benign Prostatic Hyperplasia Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Benign Prostatic Hyperplasia Market Size (2015-2020)
10.2 Benign Prostatic Hyperplasia Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Benign Prostatic Hyperplasia Market Size by Type (2015-2020)
10.4 Southeast Asia Benign Prostatic Hyperplasia Market Size by Application (2015-2020)

11 India
11.1 India Benign Prostatic Hyperplasia Market Size (2015-2020)
11.2 Benign Prostatic Hyperplasia Key Players in India (2019-2020)
11.3 India Benign Prostatic Hyperplasia Market Size by Type (2015-2020)
11.4 India Benign Prostatic Hyperplasia Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Benign Prostatic Hyperplasia Market Size (2015-2020)
12.2 Benign Prostatic Hyperplasia Key Players in Central & South America (2019-2020)
12.3 Central & South America Benign Prostatic Hyperplasia Market Size by Type (2015-2020)
12.4 Central & South America Benign Prostatic Hyperplasia Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Abbott
13.1.1 Abbott Company Details
13.1.2 Abbott Business Overview
13.1.3 Abbott Benign Prostatic Hyperplasia Introduction
13.1.4 Abbott Revenue in Benign Prostatic Hyperplasia Business (2015-2020))
13.1.5 Abbott Recent Development
13.2 Allergan
13.2.1 Allergan Company Details
13.2.2 Allergan Business Overview
13.2.3 Allergan Benign Prostatic Hyperplasia Introduction
13.2.4 Allergan Revenue in Benign Prostatic Hyperplasia Business (2015-2020)
13.2.5 Allergan Recent Development
13.3 Astellas Pharma
13.3.1 Astellas Pharma Company Details
13.3.2 Astellas Pharma Business Overview
13.3.3 Astellas Pharma Benign Prostatic Hyperplasia Introduction
13.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Business (2015-2020)
13.3.5 Astellas Pharma Recent Development
13.4 Boehringer Ingelheim Pharma
13.4.1 Boehringer Ingelheim Pharma Company Details
13.4.2 Boehringer Ingelheim Pharma Business Overview
13.4.3 Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Introduction
13.4.4 Boehringer Ingelheim Pharma Revenue in Benign Prostatic Hyperplasia Business (2015-2020)
13.4.5 Boehringer Ingelheim Pharma Recent Development
13.5 Eli Lilly and Company
13.5.1 Eli Lilly and Company Company Details
13.5.2 Eli Lilly and Company Business Overview
13.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Introduction
13.5.4 Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Business (2015-2020)
13.5.5 Eli Lilly and Company Recent Development
13.6 GlaxoSmithKline
13.6.1 GlaxoSmithKline Company Details
13.6.2 GlaxoSmithKline Business Overview
13.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Introduction
13.6.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia Business (2015-2020)
13.6.5 GlaxoSmithKline Recent Development
13.7 Merck
13.7.1 Merck Company Details
13.7.2 Merck Business Overview
13.7.3 Merck Benign Prostatic Hyperplasia Introduction
13.7.4 Merck Revenue in Benign Prostatic Hyperplasia Business (2015-2020)
13.7.5 Merck Recent Development
13.8 Pfizer
13.8.1 Pfizer Company Details
13.8.2 Pfizer Business Overview
13.8.3 Pfizer Benign Prostatic Hyperplasia Introduction
13.8.4 Pfizer Revenue in Benign Prostatic Hyperplasia Business (2015-2020)
13.8.5 Pfizer Recent Development
13.9 Sanofi
13.9.1 Sanofi Company Details
13.9.2 Sanofi Business Overview
13.9.3 Sanofi Benign Prostatic Hyperplasia Introduction
13.9.4 Sanofi Revenue in Benign Prostatic Hyperplasia Business (2015-2020)
13.9.5 Sanofi Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Benign Prostatic Hyperplasia Key Market Segments
Table 2. Key Players Covered: Ranking by Benign Prostatic Hyperplasia Revenue
Table 3. Ranking of Global Top Benign Prostatic Hyperplasia Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Benign Prostatic Hyperplasia Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Drug Therapy
Table 6. Key Players of Dialysis
Table 7. Key Players of Other
Table 8. Global Benign Prostatic Hyperplasia Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Benign Prostatic Hyperplasia Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Benign Prostatic Hyperplasia Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Benign Prostatic Hyperplasia Market Share by Regions (2015-2020)
Table 12. Global Benign Prostatic Hyperplasia Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Benign Prostatic Hyperplasia Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Benign Prostatic Hyperplasia Market Growth Strategy
Table 18. Main Points Interviewed from Key Benign Prostatic Hyperplasia Players
Table 19. Global Benign Prostatic Hyperplasia Revenue by Players (2015-2020) (Million US$)
Table 20. Global Benign Prostatic Hyperplasia Market Share by Players (2015-2020)
Table 21. Global Top Benign Prostatic Hyperplasia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia as of 2019)
Table 22. Global Benign Prostatic Hyperplasia by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Benign Prostatic Hyperplasia Product Solution and Service
Table 25. Date of Enter into Benign Prostatic Hyperplasia Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Benign Prostatic Hyperplasia Market Size by Type (2015-2020) (Million US$)
Table 28. Global Benign Prostatic Hyperplasia Market Size Share by Type (2015-2020)
Table 29. Global Benign Prostatic Hyperplasia Revenue Market Share by Type (2021-2026)
Table 30. Global Benign Prostatic Hyperplasia Market Size Share by Application (2015-2020)
Table 31. Global Benign Prostatic Hyperplasia Market Size by Application (2015-2020) (Million US$)
Table 32. Global Benign Prostatic Hyperplasia Market Size Share by Application (2021-2026)
Table 33. North America Key Players Benign Prostatic Hyperplasia Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Benign Prostatic Hyperplasia Market Share (2019-2020)
Table 35. North America Benign Prostatic Hyperplasia Market Size by Type (2015-2020) (Million US$)
Table 36. North America Benign Prostatic Hyperplasia Market Share by Type (2015-2020)
Table 37. North America Benign Prostatic Hyperplasia Market Size by Application (2015-2020) (Million US$)
Table 38. North America Benign Prostatic Hyperplasia Market Share by Application (2015-2020)
Table 39. Europe Key Players Benign Prostatic Hyperplasia Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Benign Prostatic Hyperplasia Market Share (2019-2020)
Table 41. Europe Benign Prostatic Hyperplasia Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Benign Prostatic Hyperplasia Market Share by Type (2015-2020)
Table 43. Europe Benign Prostatic Hyperplasia Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Benign Prostatic Hyperplasia Market Share by Application (2015-2020)
Table 45. China Key Players Benign Prostatic Hyperplasia Revenue (2019-2020) (Million US$)
Table 46. China Key Players Benign Prostatic Hyperplasia Market Share (2019-2020)
Table 47. China Benign Prostatic Hyperplasia Market Size by Type (2015-2020) (Million US$)
Table 48. China Benign Prostatic Hyperplasia Market Share by Type (2015-2020)
Table 49. China Benign Prostatic Hyperplasia Market Size by Application (2015-2020) (Million US$)
Table 50. China Benign Prostatic Hyperplasia Market Share by Application (2015-2020)
Table 51. Japan Key Players Benign Prostatic Hyperplasia Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Benign Prostatic Hyperplasia Market Share (2019-2020)
Table 53. Japan Benign Prostatic Hyperplasia Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Benign Prostatic Hyperplasia Market Share by Type (2015-2020)
Table 55. Japan Benign Prostatic Hyperplasia Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Benign Prostatic Hyperplasia Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Benign Prostatic Hyperplasia Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Benign Prostatic Hyperplasia Market Share (2019-2020)
Table 59. Southeast Asia Benign Prostatic Hyperplasia Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Benign Prostatic Hyperplasia Market Share by Type (2015-2020)
Table 61. Southeast Asia Benign Prostatic Hyperplasia Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Benign Prostatic Hyperplasia Market Share by Application (2015-2020)
Table 63. India Key Players Benign Prostatic Hyperplasia Revenue (2019-2020) (Million US$)
Table 64. India Key Players Benign Prostatic Hyperplasia Market Share (2019-2020)
Table 65. India Benign Prostatic Hyperplasia Market Size by Type (2015-2020) (Million US$)
Table 66. India Benign Prostatic Hyperplasia Market Share by Type (2015-2020)
Table 67. India Benign Prostatic Hyperplasia Market Size by Application (2015-2020) (Million US$)
Table 68. India Benign Prostatic Hyperplasia Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Benign Prostatic Hyperplasia Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Benign Prostatic Hyperplasia Market Share (2019-2020)
Table 71. Central & South America Benign Prostatic Hyperplasia Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Benign Prostatic Hyperplasia Market Share by Type (2015-2020)
Table 73. Central & South America Benign Prostatic Hyperplasia Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Benign Prostatic Hyperplasia Market Share by Application (2015-2020)
Table 75. Abbott Company Details
Table 76. Abbott Business Overview
Table 77. Abbott Product
Table 78. Abbott Revenue in Benign Prostatic Hyperplasia Business (2015-2020) (Million US$)
Table 79. Abbott Recent Development
Table 80. Allergan Company Details
Table 81. Allergan Business Overview
Table 82. Allergan Product
Table 83. Allergan Revenue in Benign Prostatic Hyperplasia Business (2015-2020) (Million US$)
Table 84. Allergan Recent Development
Table 85. Astellas Pharma Company Details
Table 86. Astellas Pharma Business Overview
Table 87. Astellas Pharma Product
Table 88. Astellas Pharma Revenue in Benign Prostatic Hyperplasia Business (2015-2020) (Million US$)
Table 89. Astellas Pharma Recent Development
Table 90. Boehringer Ingelheim Pharma Company Details
Table 91. Boehringer Ingelheim Pharma Business Overview
Table 92. Boehringer Ingelheim Pharma Product
Table 93. Boehringer Ingelheim Pharma Revenue in Benign Prostatic Hyperplasia Business (2015-2020) (Million US$)
Table 94. Boehringer Ingelheim Pharma Recent Development
Table 95. Eli Lilly and Company Company Details
Table 96. Eli Lilly and Company Business Overview
Table 97. Eli Lilly and Company Product
Table 98. Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Business (2015-2020) (Million US$)
Table 99. Eli Lilly and Company Recent Development
Table 100. GlaxoSmithKline Company Details
Table 101. GlaxoSmithKline Business Overview
Table 102. GlaxoSmithKline Product
Table 103. GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia Business (2015-2020) (Million US$)
Table 104. GlaxoSmithKline Recent Development
Table 105. Merck Company Details
Table 106. Merck Business Overview
Table 107. Merck Product
Table 108. Merck Revenue in Benign Prostatic Hyperplasia Business (2015-2020) (Million US$)
Table 109. Merck Recent Development
Table 110. Pfizer Business Overview
Table 111. Pfizer Product
Table 112. Pfizer Company Details
Table 113. Pfizer Revenue in Benign Prostatic Hyperplasia Business (2015-2020) (Million US$)
Table 114. Pfizer Recent Development
Table 115. Sanofi Company Details
Table 116. Sanofi Business Overview
Table 117. Sanofi Product
Table 118. Sanofi Revenue in Benign Prostatic Hyperplasia Business (2015-2020) (Million US$)
Table 119. Sanofi Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Benign Prostatic Hyperplasia Market Share by Type: 2020 VS 2026
Figure 2. Drug Therapy Features
Figure 3. Dialysis Features
Figure 4. Other Features
Figure 5. Global Benign Prostatic Hyperplasia Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Benign Prostatic Hyperplasia Report Years Considered
Figure 9. Global Benign Prostatic Hyperplasia Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Benign Prostatic Hyperplasia Market Share by Regions: 2020 VS 2026
Figure 11. Global Benign Prostatic Hyperplasia Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Benign Prostatic Hyperplasia Market Share by Players in 2019
Figure 14. Global Top Benign Prostatic Hyperplasia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia Revenue in 2019
Figure 16. North America Benign Prostatic Hyperplasia Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Benign Prostatic Hyperplasia Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Benign Prostatic Hyperplasia Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Benign Prostatic Hyperplasia Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Benign Prostatic Hyperplasia Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Benign Prostatic Hyperplasia Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Benign Prostatic Hyperplasia Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed

以下、関連資料のご紹介

良性前立腺肥大症検査の世界市場（～2026年）

Global Benign Prostatic Hyperplasia Testing Market Size, Status and Forecast 2020-2026
MRC2-11QY11037 2020年11月25日 90Pages
当調査資料は良性前立腺肥大症検査のグローバル市場について調査・分析したレポートです。種類別（尿検査、前立腺特異抗原（PSA）血液検査、尿流動態検査、膀胱鏡検査）市場規模、用途別（病院、診断センター、クリニック、研究所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタ...

PVAフォーム塞栓粒子の世界市場（～2026年）

Global PVA Foam Embolization Particles Market Insights and Forecast to 2026
MRC2-11QY14530 2020年11月30日 110Pages
当調査資料はPVAフォーム塞栓粒子のグローバル市場について調査・分析したレポートです。種類別（50μm〜350μm、350μm〜560μm、560μm〜710μm、710μm〜1000μm、1000μm〜1400μm、1400μm〜2000μm）市場規模、用途別（子宮線維塞栓術、前立腺動脈塞栓術（良...

バイオ医薬品物流の世界市場（～2026年）

Global Bio Pharma Logistics Market Size, Status and Forecast 2020-2026
MRC2-11QY11054 2020年11月25日 92Pages
当調査資料はバイオ医薬品物流のグローバル市場について調査・分析したレポートです。種類別（ジェネリック医薬品、ブランド医薬品）市場規模、用途別（航空輸送、海上輸送、道路輸送、鉄道輸送）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓...

製薬用一酸化窒素の世界市場（～2026年）

Global Pharma-Grade Nitric Oxide Market Insights and Forecast to 2026
MRC2-11QY13700 2020年11月30日 115Pages
当調査資料は製薬用一酸化窒素のグローバル市場について調査・分析したレポートです。種類別（純度99.92％、純度99.99％）市場規模、用途別（病院、医療センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オースト...

製薬添加剤の世界市場（～2026年）

Global Pharma Excipients Market Insights and Forecast to 2026
MRC2-11QY13683 2020年11月30日 114Pages
当調査資料は製薬添加剤のグローバル市場について調査・分析したレポートです。種類別（ポリマー、アルコール、ミネラル、砂糖、その他）市場規模、用途別（経口固形剤形（OSDF）、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国...

バイオファーマの世界市場（～2026年）

Global Bio-pharma Market Insights and Forecast to 2026
MRC2-11QY03255 2020年11月20日 110Pages
当調査資料はバイオファーマのグローバル市場について調査・分析したレポートです。種類別（モノクローナル抗体、組換えタンパク質、顆粒球コロニー刺激因子（G-CSF）、インターフェロン、組換えヒトインスリン、エリスロポエチン、ワクチン、成長ホルモン、精製タンパク質、その他）市場規模、用途別（代謝性疾患、腫...

吸入ラクトースの世界市場（～2026年）

Global Inhalation Lactose Market Size, Status and Forecast 2020-2026
MRC2-11QY12382 2020年11月25日 93Pages
当調査資料は吸入ラクトースのグローバル市場について調査・分析したレポートです。種類別（粉砕式吸入ラクトース、ふるい式吸入ラクトース）市場規模、用途別（錠剤製造、カプセル製造、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓...

筋萎縮性側索硬化症（ALS）治療薬の世界市場（～2026年）

Global Amyotrophic Lateral Sclerosis Drugs Market Size, Status and Forecast 2020-2026
MRC2-11QY10828 2020年11月25日 98Pages
当調査資料は筋萎縮性側索硬化症（ALS）治療薬のグローバル市場について調査・分析したレポートです。種類別（リルゾール、エダラボン（ラジカバ）、CoQ10、ブチルフタリド、その他）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、...

筋萎縮性側索硬化症（ALS）の世界市場（～2026年）

Global Amyotrophic Lateral Sclerosis Market Size, Status and Forecast 2020-2026
MRC2-11QY10829 2020年11月25日 91Pages
当調査資料は筋萎縮性側索硬化症（ALS）のグローバル市場について調査・分析したレポートです。種類別（幹細胞治療、化学療法）市場規模、用途別（病院、診断センター、診療所、小売薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、...

変形性関節症鎮痛薬の世界市場（～2026年）

Global Drugs for Osteoarthritis Pain Market Size, Status and Forecast 2020-2026
MRC2-11QY11724 2020年11月25日 130Pages
当調査資料は変形性関節症鎮痛薬のグローバル市場について調査・分析したレポートです。種類別（経口、注射、外部）市場規模、用途別（医療、パーソナルケア）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、...

良性前立腺肥大症検査の世界市場（～2026年） Benign prostatic hyperplasia (BPH) is a condition occurring in men when the prostate gland is enlarged. Benign prostatic hyperplasia is also termed as benign prostatic hypertrophy or benign prostatic obstruction. Prostate gland grows in primarily two phases, firstly during puberty when the size of t…
PVAフォーム塞栓粒子の世界市場（～2026年） Market Analysis and Insights: Global PVA Foam Embolization Particles Market The global PVA Foam Embolization Particles market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global PVA Foam Embolization Particles Scope and Market Si…
透析製品・サービスの世界市場（～2026年） The demand of Dialysis Products and Services is increasing driven by patients with chronic kidney disease is rising rapidly. Market Analysis and Insights: Global Dialysis Products and Services Market The global Dialysis Products and Services market size is projected to reach US$ 96 million by 2026, …
糖尿病治療・ドラッグデリバリーの世界市場（～2026年） Market Analysis and Insights: Global Diabetes Therapy and Drug Delivery Market The global Diabetes Therapy and Drug Delivery market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Diabetes Therapy and Drug Delivery Scope and …
次世代糖尿病治療・ドラッグデリバリーの世界市場（～2026年） Next generation diabetic therapy and drug delivery systems are used to improve the adherence to insulin in diabetic patients to reduce the risk of complications related to sudden change in the blood sugar level. The market growth is attributed to the rise in the number of diabetic patients globally …